echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The State Drug Administration revised the instruction manual for quick-acting heart-saving pills, requiring warning signs to include "pregnant women banned"

    The State Drug Administration revised the instruction manual for quick-acting heart-saving pills, requiring warning signs to include "pregnant women banned"

    • Last Update: 2021-03-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In accordance with the revised requirements, quick-acting heart-saving pill instructions should include the prohibition of pregnant women, "adverse reactions" should increase nausea, vomiting, dry mouth, headache, dizziness, rash, itching, redness, fatigue, allergies and allergic reactions, "taboo" should be added "pregnant women disabled" and "allergic to this product and the ingredients contained in the disablement", "precautions" should increase the use of allergic physique.
    Quick-acting heart-saving pills for Tianjin Zhongxin Pharmaceutical Group Co., Ltd., the sixth Chinese medicine factory's exclusive varieties, is commonly used heart disease first aid drugs, viable gas live blood, pain relief, increase coronary blood flow, relieve angina, used for hysteresis-type coronary heart disease and angina.
    public information shows that the product was modified in August 2016 in the contents of the manual without warning, "adverse reactions" and "taboo" items are "not clear", "precautions" include pregnant women disabled, allergy history of people with caution.
    according to the announcement of the State Drug Administration, the license holder of the product shall, in accordance with the relevant provisions and in accordance with the revised requirements of the corresponding instructions, report the instructions to the provincial drug regulatory department for the record by April 13, 2021.
    of the amendment relates to the drug label, it shall be revised together, and the instructions and other contents of the label shall be consistent with the original approval content.
    the original drug instructions for medicines produced on the date of filing.
    Drug market license holders shall replace the factory-issued drug instructions and labels within 9 months after filing, conduct in-depth research on the mechanism for the occurrence of new adverse reactions, take effective measures, do a good job in publicity and training on drug use and safety issues, and guide physicians and patients to use drugs rationally.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.